Blockbuster Drug Lands First-Line Indication for HER2-Positive Breast CancerBlockbuster Drug Lands First-Line Indication for HER2-Positive Breast Cancer
(MedPage Today) — The FDA approved trastuzumab deruxtecan (T-DXd; Enhertu) in combination with pertuzumab (Perjeta) for the first-line treatment of adults with unresectable or metastatic HER2-positive breast cancer.
Approval was based on results…
Awareness of BRCA Status Drives Aggressive Surgery in Early-Onset Breast CancerAwareness of BRCA Status Drives Aggressive Surgery in Early-Onset Breast Cancer
(MedPage Today) — At the San Antonio Breast Cancer Symposium, investigators from an international consortium reported that knowledge of BRCA1/2 mutation status strongly influenced surgical decision-making in young patients with stages I-III breast…
Preop RT May Boost Response to Chemo-Immunotherapy in High-Risk Early Breast CancerPreop RT May Boost Response to Chemo-Immunotherapy in High-Risk Early Breast Cancer
(MedPage Today) — SAN ANTONIO — Preoperative radiotherapy (RT) plus PD-1 inhibitor pembrolizumab (Keytruda) significantly increased immune activation and tumor response in node-positive hormone receptor-positive (HR+)/HER2-negative breast cancer…
No Increased Breast Cancer Risk With Menopausal Estrogen in BRCA CarriersNo Increased Breast Cancer Risk With Menopausal Estrogen in BRCA Carriers
(MedPage Today) — SAN ANTONIO — Menopausal hormone therapy (MHT) did not increase breast cancer risk in women with BRCA mutations, according to a study reported here.
In fact, women who used estrogen-only MHT had a significantly lower risk…
How Were GLP-1 Drugs and Bone Health Linked?How Were GLP-1 Drugs and Bone Health Linked?
(MedPage Today) — You passed medical training, now see if you can pass our weekly quiz (MedPage Today) — You passed medical training, now see if you can pass our weekly quiz
Ozempic may offer a surprising bonus benefit for brain healthOzempic may offer a surprising bonus benefit for brain health
A new analysis suggests that people with type 2 diabetes who use GLP-1 medications like Ozempic, Trulicity or Victoza may be less likely to develop epilepsy than those taking DPP-4 inhibitors. Semaglutide showed the strongest connection to lowered risk. Researchers caution that the findings show an association, not proof of cause and effect. More rigorous Read More
One GLP-1 Drug May Be Better Than Rivals for Glaucoma RiskOne GLP-1 Drug May Be Better Than Rivals for Glaucoma Risk
(MedPage Today) — Use of the dual GIP/GLP-1 drug tirzepatide (Mounjaro, Zepbound) was associated with a significantly reduced risk of glaucoma compared with GLP-1 drugs among patients with type 2 diabetes, a large retrospective cohort study suggested… (MedPage Today) — Use of the dual GIP/GLP-1 drug tirzepatide (Mounjaro, Zepbound) was associated with a significantly Read More
Risk-Based Screening Works as Well as Yearly Checks After 40 in Finding Breast CancersRisk-Based Screening Works as Well as Yearly Checks After 40 in Finding Breast Cancers
A study of more than 45,000 women found that screening women according to their level of risk was as effective in detecting tumors as the one-size-fits-most screening currently recommended.
Study Makes the Case for Replacing Annual Breast Cancer ScreeningStudy Makes the Case for Replacing Annual Breast Cancer Screening
(MedPage Today) — SAN ANTONIO — Risk-based breast cancer screening proved noninferior for detecting clinically significant tumors in a randomized trial, though outside experts raised concerns and a major medical group said the findings do not…
More Support for Omitting Lymph Node Biopsy in Low-Risk Early Breast CancerMore Support for Omitting Lymph Node Biopsy in Low-Risk Early Breast Cancer
(MedPage Today) — SAN ANTONIO — Many patients with early breast cancer can safely skip sentinel lymph node biopsy (SLNB), results of a large Dutch study suggested.
After 5 years, the regional recurrence-free survival (RRFS) rate was 96.6…